Category Archives: News

Bain Capital Announces Sale of Severo 246 in Rome Following Full Repositioning

BainCapital

LONDON and ROME — April 20, 2026 – Bain Capital, a leading global private investment firm, today announced the sale of Severo 246, a fully repositioned office building located on Via Cristoforo Colombo in Rome.

The transaction marks the successful execution of a multi-year asset transformation strategy, under which Bain Capital repositioned a legacy single-tenant office into a modern, high-quality workspace aligned with current occupier demand. Severo 246 comprises approximately 12,000 sqm of office space in the Greater EUR district, a well-established business area in the capital.

Following the departure of the incumbent tenant, the firm undertook a comprehensive refurbishment and leasing programme, including the redevelopment of internal layouts, upgrades to common areas, and the introduction of modern amenities. The building was subsequently fully pre-leased ahead of completion and delivered to a new occupier in 2025.

Severo 246 is located on Via Cristoforo Colombo, a major arterial route equidistant from Rome’s city centre and the EUR office district, and benefits from strong connectivity and proximity to a range of corporate occupiers.
“This transaction reflects our ability to identify underutilised assets and reposition them through hands-on execution,” said David Cullen, a Partner on Bain Capital’s Europe Real Estate team. “We acquired a single-tenant building with leasing risk and transformed it into a modern, fully leased asset aligned with tenant demand. It is a strong example of how we create value through disciplined asset management and local execution.”

“Severo 246 is representative of our broader approach in Europe, where we focus on situations that require operational expertise and capital investment to unlock value,” said Javier Ortigosa, an Operating Partner at Bain Capital. “From refurbishment through leasing and delivery, this was a full-cycle investment that demonstrates the strength of our platform.”

The investment formed part of Bain Capital’s Europe Real Estate strategy, which focuses on repositioning and developing high-quality assets across living, logistics, hospitality and office sectors in supply-constrained markets.

Financial terms of the transaction were not disclosed.
Advisors

JLL and Cushman & Wakefield act as sell side advisors to Savills Investment Management SGR and Bain Capital. Gatti Pavessi Bianchi Ludovici provided legal counsel on the transaction.

ENDS

About Bain Capital
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, portfolio companies, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,900 employees, and approximately $225 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).

 

Categories: News

Tags:

IK Partners to acquire Selatek from Amplio

IK Partners

IK Partners (“IK”) is pleased to announce that the IK X Fund (“IK X”), has signed an agreement to invest in SELATEK Holding AB (“Selatek” or “the Group”), a leading Swedish technical installation platform. IK will succeed Amplio I, a fund advised and managed by Amplio Private Equity AB (“Amplio”), as lead investor. Financial details of the transaction are not disclosed and completion is subject to customary regulatory approvals.

Headquartered in Stockholm, Sweden, Selatek is a technical installation platform, specialising in Security, Electrical and Automation solutions across buildings, infrastructure and industrial environments, with a strong focus on security-sensitive operations. Established in 2022 following Amplio’s acquisition of Levinsgruppen in November 2021, the Group brings together several local technical service providers under a common structure.

Selatek operates a decentralised model, where its subsidiaries retain strong local brands and customer relationships, while benefiting from shared resources, technical expertise and centralised support functions at the Group level. Through close collaboration within regional clusters, Selatek is able to achieve a high degree of workforce flexibility and cross-sale opportunities. Operating across more than 30 locations in Southern and Central Sweden, the Group has over 900 full-time employees who serve a broad and loyal base of nearly 6,000 customers.

Under IK’s ownership, Selatek will continue to pursue organic growth in its core disciplines, with an increasing focus on more complex security, automation and electrical installations and a higher share of service revenues. The Group will also look to leverage IK’s extensive experience in executing strategic cross-border M&A to accelerate its expansion across the Nordics, while working in close partnership to drive operational improvements, including procurement and workforce planning.

Magnus Löfgren, Chief Executive Officer of Selatek, said: “We are excited to confirm the formation of this new partnership with IK. With their strong expertise in the Nordic Industrials sector, we see a clear opportunity to further accelerate our development — building on our proven model of combining entrepreneurial local companies with a structured platform for growth. Together, we will continue to drive value through targeted acquisitions, while further strengthening our operational performance, cross-business collaboration and efficiency across the Group. We would like to thank the team at Amplio for their strong support and partnership over the past few years. They have played an important role in shaping the platform we have today and we now look forward to taking the next step in our journey together with IK.”

Carl Jakobsson, Partner at IK and Advisor to the IK X Fund, commented: “In a time where security, electricity capacity and automation are crucial topics for society, Selatek has proven itself as a leading technical installation provider in the Nordics, with a differentiated positioning that has consistently outperformed the broader market. We are confident that the Group’s robust organic growth, attractive M&A pipeline and scope for operational improvements will support its continued development, while preserving the successful decentralised operating model that is so highly valued by its customers. We look forward to working alongside Magnus and his team to support this next phase of development.”

Marcus Planting-Bergloo, Managing Partner at Amplio, added: “It has been a privilege to support Selatek over the past four and a half years, during which the business has delivered strong growth. Throughout our partnership, the Group expanded its footprint across Sweden and strengthened its service offering and technical capabilities through a series of carefully selected acquisitions. Today, it is uniquely positioned as the only integrated end-to-end discipline specialist in the Swedish market and we are proud to have been part of that journey. We look forward to following Selatek’s continued success and wish Magnus, his team and IK all the very best in their new partnership.”

For further questions, please contact:

Selatek
Magnus Löfgren, Chief Executive Officer
Phone: +44 (0)702 096 614
magnus.lofgren@selatek.se

IK Partners
Vidya Verlkumar, Director of Communications and Marketing
Phone: +44 (0)7787 558 193
vidya.verlkumar@ikpartners.com

Amplio Private Equity
Marcus Planting-Bergloo, Managing Partner
Phone: +46 (0)702 291 185
planting@amplio.se

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €20 billion of capital and invested in over 210 European companies. IK supports companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit ikpartners.com IK is an affiliate of Wendel. For more information, visit wendelgroup.com

Read More 

About Amplio Private Equity

Established in 2024 by the former Segulah team, Amplio is a Swedish private equity firm specialising in the Nordic lower mid-market with a strong track record and long experience of developing companies in close cooperation with skilled entrepreneurs, business leaders and industrial experts. Amplio has a distinct sector focus on Business Services and IT & Technology Services, combined with strong buy-and-build focus. To ensure long term structural growth we invest, with sustainability in focus, into markets fuelled by three major themes: ‘Sustainable Solutions’, ‘Digital Business Efficiency’ and ‘Smart Urbanisation’. For more information, visit amplio.se

Read More 

Categories: News

Tags:

Eurobio Scientific signs definitive agreement to acquire CareDx’s transplant lab production division

IK Partners

Acquisition of CareDx’s ‘lab products’ portfolio creates new opportunities for growth and innovation in the fast growing transplant diagnostics market 

  • Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader
  • Creation of a global leading provider of kits for transplantation genomics
  • Acquisition of a 100% proprietary products portfolio
  • Deeper capabilities and larger scale with technological and commercial complementarities

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro medical diagnostics for transplantation, oncology and infectious diseases, today announces that it has entered into a definitive agreement to acquire the Lab Products division of CareDx, a US global precision medicine company focused on transplantation.

Through the acquisition of CareDx’s Lab Products division, the transaction brings together two highly complementary portfolios in human leukocyte antigen (“HLA”) typing and transplantation diagnostics. It combines Eurobio Scientific affiliate GenDx’s expertise in next-generation sequencing (“NGS”) assays, software and global commercial footprint, with CareDx’s portfolio of HLA-typing and transplant monitoring kits as well as its market leading customer service.

Strategic Rationale

This acquisition enables GenDx to offer a more comprehensive portfolio across the transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions. The combined entity will offer an expanded portfolio of molecular assays, reagents, and software, with the aim of enabling laboratories to streamline operations and improve clinical outcomes.

The integration of CareDx’s LabProducts division strengthens GenDx’s presence in key markets, including the United States, Europe and Asia-Pacific, while enhancing its ability to serve both research and clinical laboratories.

Key Highlights

  • Expanded Product Portfolio: Integration of CareDx’s HLA typing kits, including real-time polymerase chain reaction (“PCR”) and NGS-based solutions, with GenDx’s NGS assays and software platforms
  • Global Commercial Scale: Enhanced distribution capabilities and customer access across major transplantation markets
  • Technology Synergies: Acceleration of innovation in high-resolution HLA typing, hybrid capture, and transplantation monitoring workflows
  • Operational Efficiencies: Opportunities to streamline manufacturing and supply chain operations

Leadership Commentary

“This acquisition marks a significant milestone in our mission to advance precision medicine in transplantation,” said Denis Fortier, CEO of Eurobio Scientific. “By combining our technological leadership with CareDx’s strong Lab Products portfolio, we are uniquely positioned to deliver comprehensive solutions to transplant laboratories worldwide.”

John Hanna, CEO of CareDx, added: “This transaction allows us to further focus on our core strengths in U.S.‑based Precision Medicine Diagnostic Testing Services and Patient and Digital Solutions, while ensuring that our Lab Products business continues to thrive under Eurobio’s leadership.”

Transaction Details

The transaction is subject to customary closing conditions and regulatory approvals. Under the terms of the agreement, Eurobio Scientific will acquire CareDx’s Lab Products business in cash for an equivalent of €145 million ($170 million), subject to customary adjustments.

Following closing, the LabProducts division will be integrated into GenDx’s operations, with a focus on maintaining continuity for customers, partners, and employees.

Eurobio Scientific is represented by TD Cowen and Kahn Partners in this transaction.  CareDx is represented by Rothschild & Co. and Fenwick.

Contacts

Groupe Eurobio Scientific
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80

Actus
Mathieu Calleux
Investors Relations Tel. +33(1) 53 65 68 68 – eurobio-scientific@actus.fr

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy. Eurobio Scientific’s reference shareholder is the Eurobio Development Holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside IK Partners, “Pépites et Territoires” by AXA & NextStage AM investment program managed by NextStage AM as well as Jérome de Castrie. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label. Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More 

Categories: News

Tags:

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

No Comments
BainCapital

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –

– Lead program afimetoran, a potential best-in-disease oral therapy for lupus, to complete Phase 2 trial in 2H 2026 before commencing pivotal development program –

– Saqib Islam, Chief Executive Officer, leads established executive team with proven track record in drug development and global commercialization of first- and best-in-class medicines –

– $300 million Series A financing led by Bain Capital supports operations into late-stage clinical development –

STAMFORD, Conn. and BOSTON – April 15, 2026 –  Beeline Medicines Corporation (“Beeline Medicines” or “the Company”), a clinical-stage biotechnology company, today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. Originally formed in July 2025, the Company’s initial portfolio is comprised of five programs in-licensed from Bristol Myers Squibb (NYSE: BMY, “BMS”), each of which is a mechanistically-guided, highly-selective therapeutic candidate with the potential to meaningfully improve the long-term health and outlook for patients living with a broad array of devastating immune-mediated conditions. With an established executive team and backed by a $300 million Series A financing led by Bain Capital, Beeline Medicines is poised to define the future of care for patients in need of life-changing treatments.

“Today marks an important milestone as Beeline Medicines debuts with a clear purpose: to deliver new, clinically significant treatment options for people living with autoimmune and inflammatory diseases,” said Saqib Islam, Chief Executive Officer of Beeline Medicines. “We are building a company with the scientific and operational rigor required to urgently deliver durable, transformative innovations to address the substantial unmet needs of this patient community. Our lead program, afimetoran, is a once-daily oral investigational therapy with the potential to change the treatment paradigm for lupus patients. As our Phase 2 trial nears completion, we are preparing for pivotal development of afimetoran, and we expect several additional clinical trials to start across our pipeline over the next 12 months.”

Differentiated Pipeline of Precision Therapies

Beeline Medicines is advancing a differentiated pipeline of precision therapies grounded in validated biology, powered by potential best-in-class molecular designs, and driven by an efficient clinical development strategy that prioritizes addressing high unmet patient needs. This mechanistically informed approach enables targeting of the underlying causes of immune-mediated diseases, restoration of immune balance, and the opportunity to dramatically improve outcomes for patients.

  • Afimetoran: Beeline Medicines’ lead program is a selective, small molecule, once-daily, equipotent TLR7/8 inhibitor that has the potential to be a best-in-disease oral therapy for lupus. Afimetoran established early clinical proof-of-concept in a Phase 1b study in cutaneous lupus erythematosus (CLE), and in May 2025 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of systemic lupus erythematosus (SLE). A Phase 2 study in SLE is ongoing and expected to complete in the second half of 2026, after which Beeline Medicines intends to commence its pivotal development program.
  • BMS-986326: A novel IL-2-CD25 fusion protein in Phase 1b development for atopic dermatitis and lupus (CLE and SLE); it is designed to address limitations of prior IL-2-directed therapies through improved selectivity for regulatory T cells (Treg) by slowly releasing IL-2 and providing pharmacokinetic (PK)/pharmacodynamic (PD) properties that drive potential for best-in-class Treg expansion and extended dosing intervals.
  • Lomedeucitinib (formerly BMS-986322): A potent, small molecule, once-daily, oral, allosteric TYK2 inhibitor that achieved positive proof-of-concept in a placebo-controlled Phase 2 study in plaque psoriasis, with potential for first-in-class development in rare immunological diseases.

Beeline Medicines’ emerging pipeline includes two IND-stage next-generation biologics with novel mechanisms focused on the IL-18 and IL-10 pathways, both validated approaches for addressing inflammation across multiple indications, including in gastrointestinal inflammatory conditions. The shared disease biology across the Company’s pipeline enables long-term, sustained growth through indication expansion, combination approaches, and business development.

“Immune-mediated diseases remain an area of profound need, and we believe that Beeline Medicines is positioned to redefine treatment across multiple underserved autoimmune and inflammatory conditions,” said Dr. Nathalie Franchimont, Chief Medical Officer of Beeline Medicines. “We believe afimetoran, our lead program in lupus, reflects the differentiated, patient-centered approach that we will bring to this field: a precision oral therapy designed to address the underlying drivers of lupus biology in a way that improves clinical outcomes and fits into patients’ lives. With three programs in the clinic and two additional candidates advancing toward first-in-human studies, we aim to move care beyond symptom management to immune system recalibration, durable disease control, and meaningful improvements for patients.”

Industry-Leading Management Team and Board of Directors

In conjunction with the official launch, Beeline Medicines announced its founding executive leadership team, bringing deep experience across autoimmune and inflammatory disease drug discovery and development, regulatory approvals, global commercialization, capital formation, and business and corporate development. Beeline Medicines’ executive team has contributed to the approval and launch of over a dozen medicines combined over their careers, impacting the lives of millions of people worldwide.

  • Saqib Islam, Chief Executive Officer
  • Badreddin Edris, Ph.D., President & Chief Operating Officer
  • Nathalie Franchimont, M.D., Ph.D., Chief Medical Officer
  • Kristin Patterson, Ph.D., Chief Technical Operations Officer
  • Daniel Pichl, Chief People Officer

Beeline Medicines has also assembled a seasoned Board of Directors spanning renowned R&D leaders, pharmaceutical executives, and life science investors to support the Company’s strategic direction and growth. The Board is chaired by Daniel S. Lynch, who has served alongside Robert Plenge, M.D., Ph.D., Nicholas Downing, M.D., Adam M. Koppel, M.D., Ph.D., and Andrew Kaplan since the closing of the Company’s Series A financing in July 2025. Saqib Islam, Chief Executive Officer of Beeline Medicines, also serves as a Board member. More recently, Martin Mackay, Ph.D., has joined the Board of Directors, bringing more than three decades of global R&D leadership experience, including executive roles at Pfizer, AstraZeneca, and Alexion Pharmaceuticals, and Board positions at Novo Nordisk, Charles River Labs, and Kailera Therapeutics.

“With a category-defining portfolio, world-class executive leadership team, and operational excellence, Beeline Medicines is positioned to deliver medicines that can change the lives of people with devastating immunological conditions,” said Mr. Lynch. “I look forward to supporting Beeline Medicines in building an impactful immunology company that develops these urgently needed therapies.”

About Beeline Medicines

Beeline Medicines is a clinical‑stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people living with autoimmune and inflammatory diseases. With a portfolio of potential best-in-class and first-in-disease therapeutic candidates that directly target key pathways governing dysregulated immunological and inflammatory responses, the Company is developing medicines that have the opportunity to provide durable, life-changing impact. Led by an established executive team and backed by world-class life science investors, each day Beeline Medicines is determined to bring the scientific rigor and operational excellence to get to what matters for patients – realizing a world where people with immune-mediated diseases can live life fully.

For more information, visit www.BeelineMedicines.com and follow on LinkedIn.

Categories: News

Tags:

KKR and Samsung SDS Form Strategic Partnership to Drive Long-Term Value Creation

KKR

KKR to become active minority investor through KRW 1.22 trillion ($820 million) investment

SEOUL, South Korea–(BUSINESS WIRE)– KKR, a leading global investment firm, and Samsung SDS, a leading enterprise IT solutions company (the “Company”) and a member of Samsung Group, today announced a strategic partnership to support Samsung SDS’ next phase of growth and long-term value creation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414166241/en/

Under the strategic partnership, KKR, through funds managed by KKR, and Samsung SDS will closely collaborate on a range of value creation initiatives for the Company, including supporting organic and inorganic growth strategies, accelerating the Company’s expansion as a full‑stack AI solutions provider, and expanding into new business areas. KKR will also serve in an active advisory capacity to Samsung SDS’ management team, particularly in areas including M&A, capital allocation, and supporting the Company’s efforts to pursue strategic growth opportunities globally.

In connection with the strategic partnership, funds managed by KKR have entered into definitive agreements to acquire KRW 1.22 trillion ($820 million) of convertible bonds newly issued by Samsung SDS. The Company intends to utilize the investment, together with its existing resources, to strengthen its infrastructure and capabilities and reinforce its competitive position in key growth areas, including end-to-end AI transformation services.

Established in 1985, Samsung SDS is a leading provider of enterprise IT solutions. The Company delivers a comprehensive suite of services spanning cloud, digital transformation, artificial intelligence, and logistics to a global customer base across industries. As a core strategic priority, the Company continues to expand its AI transformation (AX) business through sustained investments in AI infrastructure, platforms, and capabilities. With approximately 26,000 employees and annual revenue of KRW 14 trillion, Samsung SDS combines scaled delivery capabilities with deep technical expertise and is well positioned to support its customers’ evolving needs for cloud adoption and digital transformation.

Chung Ho Park, Partner and Head of Korea at KKR, said, “This unique strategic partnership brings together Samsung SDS, part of one of Korea’s most established conglomerates, with KKR’s global experience in long-term value creation. Against a backdrop of increasing demand for digital transformation and AI solutions, we have strong conviction in Samsung SDS’ market leadership and growth potential by playing a critical role in advancing Korea’s digital capabilities and infrastructure. We look forward to leveraging KKR’s global network, deep local experience, and operational expertise to take the Company to its next stage of transformation as hands-on, active investors to drive long-term value creation for all shareholders and stakeholders.”

Jun Hee Lee, President and CEO of Samsung SDS, commented, “We are delighted to welcome KKR as a strategic investor as we continue to advance our growth strategy. Through this strategic collaboration, we will actively explore a wide range of growth opportunities, including M&A, by leveraging KKR’s expertise accumulated in global capital markets. Through cooperation between the two companies, we will continue to work closely together to enhance Samsung SDS’ corporate value and strengthen its foundation for global growth.”

KKR is making this investment primarily from its Asia Fund IV. This investment builds on KKR’s long-standing track record of investing in leading Korean companies with recent examples including Samhwa, MUSINSA, HD Hyundai Marine Solution, and SK Eternix. It also adds to KKR’s experience in the IT services sector globally, including FUJI SOFT, a leading system integrator in Japan; DATAGROUP, a leading IT solutions provider in Germany; a global full-lifecycle digital services transformation company Ness Digital Engineering; Devoteam, an IT and cloud services company focused on enabling digital transformation in France; and leading hybrid IT services provider Ensono in the US.

The transaction is expected to close during the second quarter, subject to customary closing conditions. Additional details of the transaction were not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Samsung SDS

Founded in 1985, Samsung SDS is an ICT company with solutions which have been leading the digital transformation and innovation of clients for over 30 years across a wide range of industries. With operations in more than 40 countries, Samsung SDS’ solutions utilize advanced analytics platforms, AI, blockchain, cloud technologies to serve a diverse range of industries including financial services, smart manufacturing, global logistics, and retail.

Media Contacts

For KKR:

Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

James Jarman
+65 8870 6452
James.Jarman@kkr.com

For Samsung SDS:

pr_sds@samsung.com
+82 2 6155 1026

Source: KKR

 

Download PDF

Categories: News

Tags:

Ardian announces sale of Netco Group, a leading European provider of maintenance services to Eurazeo

Ardian

Eurazeo, through its Capital team* has entered into a definitive agreement to acquire a majority stake in Netco Group (“Netco”), a leading European provider of critical maintenance services for conveyor systems in vital industries, from Ardian, a global private investment firm, and Netco’s management team. Netco’s founders will make a significant reinvestment alongside Eurazeo, reflecting a shared ambition to accelerate the Group’s development and market positioning. Completion of the transaction is subject to customary formalities and obtaining relevant regulatory approvals.

Founded in Bordeaux in 1902 by the Perriez family, Netco has established itself as a European leader and international operator in the general maintenance and servicing of conveyor systems across a wide range of production sectors, including minerals, energy, recycling & waste, machinery, agri-food, metallurgy and pharmaceutical & chemicals. The Group operates in critical industries where process continuity is essential, and where any conveyor failure may lead to substantial and irreversible production losses, making its services highly strategic for its clients.

Led by Samuel and James Perriez, representing the fourth generation of the founding family, Netco has achieved global expansion through a combination of organic growth and an active acquisition strategy enabling the Group to establish a presence across four continents.

It holds market leading positions in France, Spain and the Benelux region as well as growing positions in the UK and Portugal. It also operates a network of over 100+ service points worldwide. As an integrated provider combining maintenance, distribution and PVC & PU belt-manufacturing, Netco is uniquely positioned to benefit from the growing outsourcing of maintenance services in Europe and beyond. Its markets remain resilient and fragmented, offering significant consolidation opportunities.

Eurazeo and Netco’s management team will work together to continue the Group’s development, notably through a targeted M&A strategy. Eurazeo will provide its experience in international expansion and operational investment, drawing on its presence in Europe, the United States and China, and its experience in critical Business Services – will contribute its expertise in international expansion and operational improvement.

” We are proud to invest in Netco and are excited to work alongside Samuel and James Perriez in accelerating the company’s international expansion strategy by, leveraging our global footprint and operational capabilities. This transaction reflects Eurazeo’s disciplined approach to building a portfolio of globally scalable platforms in diversified sectors, including critical Business Services, where we have developed deep expertise and where Netco’s market leadership and network density are key differentiators.” Edouard Guigou, Partner and Rémi Viel, Managing Director in the Capital team, Eurazeo

” Eurazeo is the perfect partner: It aligns with our values while fitting into the continuity of the Ardian cycle, providing the necessary support to achieve our Group’s growth ambitions.” James Perriez and Samuel Perriez, CEO and President of Netco

” We are very pleased to have supported Netco’s development over recent years and to see the Group enter a new phase of growth alongside Eurazeo. Netco has built a strong leading position in critical maintenance services across Europe, supported by a resilient business model. The group closed 20 acquisitions over our investment period, including a first one in the US. This transaction reflects the success of the strategy implemented under the exceptional leadership of Samuel and James Perriez.” Alexis Lavaillote and Maxime Sequier, Managing Directors Expansion, Ardian
*Part of Eurazeo Global Investor

List of participants

  • Ardian

    • Ardian: Alexis Lavaillote, Maxime Sequier, Leslie Parmast
    • Financial advice for sellers: Amala Partners (Jean-Baptiste Marchand, Benjamin Giner, Julien Le Guern, David Krivine)
    • Legal advice for sellers: McDermott Will & Emery (Grégoire Andrieux, Marie-Muriel Barthelet)
    • Seller’s financial due diligence: Alvarez & Marsal (Frédéric Steiner, Baptiste Rideau, Mounia Chakor Alami, Christilla Courtel)
    • Seller-side strategic due diligence: LEK Consulting (Serge Hovsepian, Stephane Claquin, Benjamin Tuchman, Charles Petracco)
    • Legal due diligence (corporate, labor, and tax) for the seller: EY (Nevenna Todorova, Jean-Christophe Sabourin, Sophie Muyard, Lionel Benant)

 

ABOUT ARDIAN

In a world of constant evolution, Ardian stands out for its ability to anticipate, adapt, and turn challenges into opportunities. As a global, diversified private markets firm with 22 offices and more than 350 investment professionals worldwide, we provide investment and customized solutions that reflect new economic dynamics and help our clients remain resilient in a changing world.
We deliver multi-local expertise and long-term performance for our investors and partners as well as shared value for the broader society. Since Ardian’s inception in 1996, our pioneering approach to diversification and our ability to offer tailor-made solutions at scale have remained the heart of our strategy.
Through commitment, knowledge and technology, we bring lasting value to our companies and contribute positively to the whole industry.
Ardian currently manages or advises $200bn for more than 1,920 clients worldwide across Private Equity, Real Assets, and Credit.
Ardian. Mastering change for lasting value.

ardian.com

 

ABOUT EURAZEO

Eurazeo is a leading European investment group with €39 billion in diversified assets under management, including €30 billion on behalf of institutional and retail clients through its private equity, private debt, real estate and infrastructure strategies. The Group supports more than 700 mid-market companies, leveraging the commitment of its 450-strong workforce, its in-depth sector expertise, its privileged access to global markets through 14 offices across Europe, Asia and the United States, and its responsible approach to value creation based on growth. The company’s institutional and family shareholding structure, and its solid financial structure, ensure its long-term viability.
Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Stockholm, Madrid, Luxembourg, Shanghai, Seoul, Singapore, Tokyo and São Paulo.
Eurazeo is listed on Euronext Paris.
ISIN: FR000121121 – Bloomberg: RF FP – Reuters: EURA.PA.

 

ABOUT NETCO GROUP

Founded in 1902 in France by the Perriez family, Netco has grown to become the European leader in the maintenance and servicing of conveyor systems, supporting critical materials of industrial processes across a wide range of sectors, including food processing, logistics, quarries, aggregates and minerals.
Headquartered in Bordeaux, the Group operates 100+ agencies across France, Spain, Belgium, the UK, Portugal, Germany and Luxembourg, and employs around 1,400+ people. While historically focused on Europe, Netco continues to pursue an ambitious international expansion strategy.
Thanks to its robust operating model, Netco has become a strategic partner for its 2,500+ customers, offering tailored solutions and ensuring continuity of their industrial operations.

Media contacts

ARDIAN

HEADLAND

ardian@headlandconsultancy.com

EURAZEO

Claire Helleputte Head of Media Relations

chelleputte@eurazeo.com+44 (0) 7442 234 254

Categories: News

Tags:

Warburg Pincus Establishes European Defence Investment Platform

Warburg Pincus logo
  • Warburg Pincus launches European Defence Investment Initiative with MEAG on behalf of Munich Re Group as an Early Backer of the Strategy 
  • Collaboration Focused on Private Equity Investments in European Defence, Security and Strategic Resilience Businesses

London and Berlin, 10 April 2026 – Warburg Pincus, the pioneer of private equity global growth investing, today announced the commencement of a dedicated European defence investment platform, reflecting the firm’s view that the sector is benefiting from sustained structural tailwinds and long-term policy support across the region. MEAG, as asset manager of Munich Re Group, will support the strategy as an early backer in the investment platform.

The proposed investment platform will complement existing capabilities while maintaining a dedicated European defence focus. As European governments and institutions accelerate investment in defence capabilities, resilience and strategic sovereignty, the proposed platform seeks to position Warburg Pincus to deploy capital into defence and adjacent strategic industries across Europe.

“Europe is undergoing a fundamental reassessment of its defence, resilience and security needs, leading to significant need for scaling of the European Defence sector,” said Tobias Weidner, Managing Director and head of the European Industrials team at Warburg Pincus. “We believe this creates a compelling long-term opportunity to support the growth of high-quality businesses operating in critical, strategic sectors, drawing on our experience investing in Aerospace and Defence and broader industrials.”

“Defence and security are strategically important sectors, given their role in supporting European resilience. Warburg Pincus is a natural partner based on our long-standing relationship and their deep sector expertise in Aerospace and Defence with a multi-decade track record building market-leading companies. We look forward to working together to back high-quality European businesses in this space,” said Nicholas Gartside, Member of the Board of Munich Re and Chief Investment Officer of Munich Reinsurance Company.

Warburg Pincus has a long track record of partnering with management teams and founders across Europe and globally. The firm brings significant experience across core Aerospace and Defence and adjacent industrial sectors globally, supported by more than 20 years of industrials investing and over 40 years of investing in Europe through multiple economic cycles. Current and former Aerospace and Defence platforms include Consolidated Precision Products (CPP), Triumph Group, INRCORE, Wencor Group, Extant Aerospace and TransDigm in the U.S., Inmarsat and Accelya in Europe and Quest Global in India.

In recent years, Warburg Pincus has also further strengthened its senior advisory capabilities in the defence and national security space, assembling a group of highly experienced European and transatlantic leaders. This includes:

  • Admiral Joachim Georg Rühle (Retired 4 Star Admiral), former Chief of Staff at NATO’s Supreme Headquarters Allied Powers Europe (SHAPE) and former Vice Chief of Defence of the German Armed Forces;
  • Susanne Wiegand, a senior executive with more than 20 years of leadership experience across the defence, mechanical engineering and marine industries, including as Chair and CEO of RENK Group AG and former CEO of Rheinmetall’s Electronic Solutions division;
  • Lieutenant General Jürgen-Joachim von Sandrart (Retired 3 Star General), with four decades of service in the German Army and former commander of NATO’s Multinational Corps Northeast and a senior advisor on security and defence policy in Germany; and
  • Rolf Wirtz, a senior defence executive and former officer in the German armed forces, with decades of leadership across military aircraft and UAV, defence electronics, and naval systems, including as CEO of Atlas Elektronik and as CEO of TKMS.

This deep bench of advisors is expected to work closely alongside the firm’s experienced Aerospace and Defence investment professionals based across Europe and the U.S., combining strategic, operational and policy expertise with Warburg Pincus’ global sourcing capabilities and value-creation platform.

About Warburg Pincus

Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $100 billion in assets under management, and more than 215 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.The firm is headquartered in New York with more than 15 offices globally. For more information, please visit www.warburgpincus.com or follow us on LinkedIn and YouTube.

Media contact:

Alice Gibb – Director, Europe Communications
Alice.gibb@warburgpincus.com
+44 207 306 3090

Categories: News

Tags:

SecurityXpert and Met WA Beveiliging Join Forces to Form a Specialized Healthcare Security group

Karmijn Kapitaal

IJsselstein, April 9, 2026 – Investment company Karmijn has acquired SecurityXpert. Following this acquisition, the security company will join forces with Met WA Beveiliging under Curantis Veiligheidsgroep, a newly established group of specialized security companies focused on the healthcare sector. The transaction was facilitated by M&A advisor Marktlink

The collaboration is aimed at bringing together specialized companies in healthcare security, with the goal of further
deepening and scaling expertise, capacity, and service offerings. SecurityXpert and Met WA Beveiliging will continue
to operate under their own names while collaborating in the areas of training, knowledge sharing, and operational
support. The strategy focuses on both organic growth and expansion through targeted acquisitions.
SecurityXpert was founded in 1997 by Conrad van Tuijl and has grown into a security organization with
approximately 60 security officers, based in IJsselstein. The company specializes in healthcare security and related
services, including static guarding, event security, and traffic coordination. With a strong regional presence in the
central Netherlands, SecurityXpert has in-depth knowledge of healthcare institutions and their environments. With
clients such as the Diakonessenhuis and Kwintes, the company has established a strong market position.

Specialized Group
The combination of Met WA Beveiliging and SecurityXpert creates a group with complementary expertise and
broader operational coverage within the healthcare sector. Jasper Kamman, Managing Director of Met WA
Beveiliging: “The increasing complexity of healthcare security requires specific expertise and a different approach
compared to traditional security services. By bringing SecurityXpert and Met WA together within Curantis, we can
further develop and scale this knowledge. This enables us to better support healthcare institutions with solutions
that align with day-to-day practice.”

The collaboration aligns with the investment strategy of Karmijn Kapitaal, which focuses on building a specialized
security group. Cilian Jansen Verplanke, Partner at Karmijn Kapitaal: “The demand for specialized security services
within the healthcare sector continues to grow. SecurityXpert has a strong regional position and an approach that
closely aligns with the day-to-day practice of healthcare institutions. With our earlier investment in Met WA
Beveiliging, we took a first step; with SecurityXpert, we are building on this foundation and strengthening our
position in the central Netherlands. Both organizations complement each other well and form a solid basis for
further growth.”

Continuity and Growth Perspective
SecurityXpert was looking for a partner that respects the company’s identity while also providing room for further
development. Conrad van Tuijl, founder of SecurityXpert: “We have built an organization that is closely aligned with
the day-to-day practice of healthcare and is available to our clients 24/7. Through this partnership, we can further
develop our services while preserving our way of working. For both employees and clients, this means continuity,
with additional opportunities for growth.”
Marktlink supported SecurityXpert throughout the process, up to and including the completion of the acquisition
and the subsequent partnership. Lars de Ruiter, on behalf of Marktlink: “The initial request from the shareholders
was driven by succession planning. With the involvement of two of Van Tuijl’s sons, this created an opportunity to
jointly consider the future of SecurityXpert, where a strategic opportunity quickly became apparent. SecurityXpert is
a distinctive player within a rapidly developing segment. Scale and specialization are becoming increasingly
important, while the demand for security services in healthcare environments continues to grow. After the company
was carefully prepared for sale, this ultimately led to the acquisition by Karmijn and the partnership with Met WA
Beveiliging. This adds a strong regional player that fits well within Karmijn’s buy-and-build strategy.”

Categories: News

Tags:

Bain Capital invests in Positec to accelerate global growth and next-gen innovation

BainCapital

Hong Kong, April 10, 2026 – Bain Capital, a leading global private investment firm, today announced an investment in Positec Group (“Positec”), a leading global player in cordless power tools and advanced outdoor power equipment. The investment will support Positec’s next phase of international growth, product innovation, and expansion into high-growth categories.

Founded in 1994, Positec has built a strong global position through its focus on innovation, advanced battery technology, and a growing leadership in automation. Through its flagship brands, Worx and Kress, the company serves customers across key markets including North America and Europe, with a product portfolio spanning home improvement tools and professional-grade tools, as well as fast-growing categories such as residential and commercial robotic solutions.

The partnership with Bain Capital will support Positec’s continued shift toward electrification and robotics, while strengthening its global distribution, brand development, and operational capabilities. The investment also enhances the company’s financial flexibility as it scales its presence across existing and new markets.

“We are pleased to partner with Positec at this important stage of its journey,” said Michael Hui, a Partner at Bain Capital. “Over the past three decades, Positec has demonstrated an exceptional ability to build globally competitive brands and drive product innovation. We look forward to supporting the company as it continues to expand internationally, invest in next-generation technologies, and further strengthen its market leadership.”

Don Gao, Founder and President of Positec, said: “This partnership marks an important step in Positec’s evolution. With Bain Capital’s support, we will accelerate our innovation in robotics and electrification, expand our global footprint, and continue redefining how tools are designed, powered, and used. We remain focused on building products and brands that deliver meaningful value to customers worldwide.”

###

About Bain Capital

Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. We have 24 offices on
four continents, more than 1,985 employees, and approximately US$215 billion in assets under management.
About Positec

Founded in 1994, Positec Group is a global technology-driven company focused on the electrification, robotization, and digitization of power tools and outdoor power equipment. The company has developed a portfolio of premium international brands, including Worx and Kress, serving customers in nearly 70 countries and regions worldwide. Positec employs more than 4,000 people globally and continues to invest in innovation to shape the future of how tools are designed, powered, and used.

Categories: News

Tags:

Bain Capital and Evergreen Medical Properties Acquire Portfolio of Six Medical Outpatient Facilities in Atlanta Metropolitan Area

BainCapital

ATLANTA and BOSTON – April 9, 2026 – Bain Capital’s Real Estate team (“Bain Capital”) and Evergreen Medical Properties (“Evergreen”) today announced the acquisition of a medical outpatient building portfolio consisting of six assets totaling approximately 665,000 square feet in the Atlanta metropolitan area.  The private, off-market purchase was completed via a partnership between Bain Capital and Evergreen that focuses on acquiring, renovating, and operating mission-critical medical outpatient buildings.

The Class-A medical outpatient buildings are anchored by Northside Hospital, a leading, award-winning healthcare provider operating five acute-care hospitals and nearly 500 outpatient facilities across 25 counties in the Atlanta MSA. Northside leads the U.S. in newborn deliveries and is among Georgia’s top providers of cancer care, sports medicine, cardiovascular and surgical services. The portfolio is 93% leased and features other dynamic tenants spanning diverse specialties and high-acuity services.  The assets are located in “Pill Hill” and Alpharetta, two high-demand, affluent Atlanta submarkets.

“We’re pleased to expand our presence in Atlanta, a high-conviction market, as well as our relationship with Northside Hospital as we execute a value creation plan alongside the Evergreen team that enhances the facilities’ ability to better serve patients across the Atlanta area,” said Lukas Gregg, a Managing Director at Bain Capital.  “This transaction is an attractive opportunity to acquire a high-quality portfolio of mission-critical assets supported by strong market dynamics and we are grateful to be the new stewards of it.”

“We’re ecstatic Northside chose to expand our relationship with some of the health system’s most strategically important medical outpatient buildings,” said Joshua Richmond, President of Evergreen Medical Properties. “We look forward to working closely with Northside as we build upon Evergreen’s strong track record of aligning capital and healthcare partners through the stewardship of mission-critical real estate.”

The acquisition of these buildings follows the partnership’s recent purchase of a two-asset portfolio in Lawrenceville, GA, also anchored by Northside Hospital.  Bain Capital and Evergreen have curated a portfolio of institutional quality medical outpatient buildings in select markets throughout the U.S. and are actively seeking to grow its 2M square foot footprint.

Northside was advised by Realty Trust Group, a national healthcare advisory firm.

###

About Bain Capital Real Estate
Bain Capital Real Estate pursues investments in often difficult-to-access sectors underpinned by enduring secular trends that drive long-term demand growth for real estate assets and services. The Bain Capital Real Estate team has invested and committed over $10.7 billion of equity across multiple sectors as of September 30, 2025. Bain Capital Real Estate focuses on assets where the team applies its deep industry expertise to accelerate impact and drive operational improvements. Bain Capital Real Estate’s strategy aligns with the value-added investment approach that Bain Capital pioneered and leverages the firm’s global platform and significant experience across asset classes to further bolster its insights and sourcing capabilities. Bain Capital is one of the world’s leading private investment firms, with approximately $219 billion of assets under management. For more information, visit https://www.baincapitalrealestate.com.

About Evergreen Medical Properties  
Evergreen Medical Properties, with offices in both Denver and Atlanta, is a full-service real estate operating company that invests, leases and manages healthcare facilities across the United States. Evergreen uses a collaborative approach to invest in strategic healthcare real estate in order to align interests and build genuine relationships with health systems and providers.  Evergreen seeks to unlock capital, enhance the operating flexibility of its partners and create durable, long-term value in each of its healthcare real estate investments.

About Northside Hospital
The Northside Hospital healthcare system is one of Georgia’s leading healthcare providers with five acute-care hospitals in Atlanta, Canton, Cumming, Duluth, and Lawrenceville and nearly 500 outpatient locations across the state. Northside Hospital leads the U.S. in newborn deliveries and is among the state’s top providers of cancer care, sports medicine, cardiovascular, and surgical services. For more information, visit: www.Northside.com.

Categories: News

Tags: